Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy (2018)
Sequence: GRKKRRQRRRQC
| Experiment Id | EXP002552 |
|---|---|
| Paper | Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy |
| Peptide | HIV TAT-Cys |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | TAT-PEG-SN38 liposomes |
| Rna Concentration | 2.5 mg/kg siRNA; 5 mg/kg SN38 equiv. |
| Mixing Ratio | protamine:siRNA = 1:0.3 |
| Formulation Format | Transferrin-targeted liposomes |
| Formulation Components | SPC/cholesterol/TAT-PEG-SN38/protamine/siRNA/DSPE-PEG-Tf |
| Size Nm | 148.00 |
| Zeta Mv | 7.80 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | HeLa xenograft nude mouse |
| Administration Route | Intravenous (tail vein) |
| Output Type | Tumor growth inhibition, biodistribution |
| Output Value | 76.8% tumor inhibition vs vehicle |
| Output Units | |
| Output Notes | IVIS imaging shows tumor accumulation; reduced tumor volume and weight |
| Toxicity Notes | No significant body weight loss |
| Curation Notes |